10:34 AM EST, 03/08/2024 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) said Friday results from its two phase 3 trials of its Eylea HD medication for patients with either wet age-related macular degeneration or diabectic macular edema demonstrated 8-milligram injections were not inferior to 2-milligram injections after 48 weeks.

Results of the phase 3 trials, in both of which the primary endpoints of vision gains were reached, were published in The Lancet, a peer-reviewed medical journal, the company said.

The US Food and Drug Administration approved 2-milligram injections of Eylea HD to treat diabetic retinopathy as well as wet age-related macular degeneration or diabetic macular edema in August 2023. The 8-milligram regimen has already been authorized by regulators in the European Union, Japan and other countries where Regeneron and Bayer AG, with whom the drug is being developed, share marketing rights.

Price: 967.38, Change: -5.93, Percent Change: -0.61